Monday, August 5, 2019

ADC Links - Aug 5th, 2019

Videos -

Antibody Drug Conjugate (ADCs) killing mouse breast cancer cells
-The first link is to a video showing cells being killed by an ADC vs its control sample.  In a world of adding clear liquids to clear liquids with very little payout, this concrete video makes me happy.  The second link is the original article, scroll down a ways and the ADC section is in there

Industry -

New Frontiers in ADC Development
The Medicine Maker
- Really interesting article with an interview from some of the major players in the ADC space.  Very long, but also very good with lots of insight into yesterday, today, and tomorrow

Antibody-drug Conjugate Market Top key Players, Size, Share, Demand, Opportunities And Forecasts To 2025
Antibody Drug Conjugate Market Size Is Estimated To Grow at a CAGR of 19% Till 2023 | Industry Trends, Key Players and Global Market Analysis By MRFR
Global Antibody-Drug Conjugate Market Size & Growth by 2019-2024: Companies, Opportunities, Challenges, Growth, Countries, RevenueAntibody Drug Conjugates (ADCs) Market Size: Analysis and In-depth Research on Industry Size, Trends, Emerging Growth Factors and Regional Forecasts to 2025
Antibody Drug Conjugates (ADCs) Market Sales Volume by Global Industrial Growth Rate, Size, Shares, Productions, Demands and Supply Analysis from 2019
Global Antibody-Drug Conjugate Market Size Forecast by 2019-2024: Applications, Geographic Regions, Opportunities, Challenges, Drivers
Antibody Drug Conjugate Market to Experience Significant Growth During the Forecast Period 2018-2025
- Can anybody explain to me why these reports exist?  And how can there possibly be twenty different companies all doing the same research and reaching the same conclusions.  There are at least 5 of these per week, and I just don't understand how there can be that many, and for the low low price of $3280 for an online PDF.  What am I missing?

Weekly Research Analysts’ Ratings Updates for Sutro Biopharma (STRO)
Mayfield Recorder
- In case you wanted to see what happens in the world of cash that flows around the science.  This is a neat little timeline of the Sutro investment ratings.  At some point, I have to wonder if Zachs Investment is just pushing recommendations around to make their customers feel like something is happening.  How can they change their rating on Sutro 5 times in two months

Polatuzumab Vedotin: First Global Approval
- Polivy is live and approved.  Here is a nice summary of its journey to get you up to speed

Single‐Use Technology in Biopharmaceutical Manufacture, Second Edition
Wiley and Sons
- Single-use is all the rage in ADC manufacture these days, take a look at Ch 27  Progress in the Development of Single-Use Solutions in Antibody-Drug Conjugate Manufacturing for the good stuff

Regulatory -

Aetna and Anthem will now pay for more kids with a devastating rare disease to get a $2.1 million drug, reversing earlier denials
Business Insider
- People said that $2.1M was too expensive for a drug treatment.  That insurance companies would never cover such a thing.  But here you have Novartis' Zolgensma doing just that.  Curing disease is a powerful thing, and with the pictures of cute kids behind it, the insurance companies will come around eventually.  This is good news for ADCs as well as they aren't cheap by any stretch either

- I can't claim to have any great insights into the world of FDA regulation within Clinical Trials, but in case any of you do, they just released a new recommendation document

Manuscripts -

Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer
Targeted Oncology
- This is a pretty unique application of ADCs to prolong progression-free survival.  They are working in combination with platinum-based chemo to target an antigen which becomes expressed as an early sign of disease recurrence

Methods in Molecular Biology
- Take a look.  If you are involved in the science of ADC conjugation, then this will be interesting

Investigation of Antibody-Drug Conjugates by Mass Spectrometry
Advancements of Mass Spec in Biomedical Research
- Put your nerd hats on, this is a deep dive into Mass Spec and its application to ADCs

Prediction of Aggregation Propensity and Monitoring of Aggregation of Antibody-Drug Conjugates (ADC) using ProteoStat® Reagents
Drug Target Review
- This is a white paper put out by Innate Pharma.  But it's also potentially a very cool assay that could be helpful in process development.  Has anyone played with this to see how process changes can affect ADC stability?  I'd be interested to see how this can apply not only across multiple constructs like they look at, but at different times during conjugation.  Specifically around cysteine reduction

Reports -

Gene Therapy
New England Journal of Medicine
- I know this isn't about ADCs, but if you're like me.  You spend an extraordinary amount of time paying attention to ADCs but only hear tangentially about Gene Therapy and its goings-on.  So, for thos of us who aren't as informed as we might like, the New England Journal of Medicine put together a fantastic report

Clinical Results -

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
Lung Cancer
- Rova-T is not dead yet.  Well, to be fair, I don't know.  But at least this report says that Japanese patients exhibited tolerable toxicity and saw partial response rates of 17%.  They conclude that this is worth further investigation, but that doesn't necessarily mean there will be

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- SeaGen keeps rolling with a 44% objective response rate in their pivotal trial.  They are getting closer and closer to bringing their second wholly owned ADC asset

Thats it for today. There are always more coming down the pike. Is there something I missed? Contact me.
- - - [Main]

No comments:

Post a Comment